Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE SODIUM PHOSPHATE versus STERI STAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE SODIUM PHOSPHATE versus STERI STAT.
DEXAMETHASONE SODIUM PHOSPHATE vs STERI-STAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone sodium phosphate is a glucocorticoid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene expression.
Binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by blocking peptide bond formation and translocation.
4-20 mg IV or IM every 4-6 hours; for cerebral edema: 10 mg IV followed by 4 mg IM/IV every 6 hours; for shock: 20 mg IV initially then 2-6 mg/kg IV bolus or 40 mg IV every 2-6 hours as needed.
Adults: 1 gram intravenously every 8 hours infused over 60 minutes.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in adults; however, the duration of action extends beyond the plasma half-life due to intracellular receptor-mediated effects.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min).
Renal excretion of unchanged drug and metabolites accounts for approximately 60-70% of elimination; biliary/fecal excretion accounts for 30-40%.
Renal excretion of unchanged drug accounts for approximately 95% of elimination; biliary/fecal elimination is minimal (<5%).
Category D/X
Category C
Corticosteroid
Corticosteroid